

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Equality impact assessment – Scoping**

**Avapritinib for treating advanced systemic mastocytosis [ID3770]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

In response to consultation, the company commented that avapritinib does not contain gelatin as an excipient. Inclusion of gelatin can be problematic for people with certain religious or cultural beliefs, particularly those of the Islamic faith for whom this product may not be considered to be Halal. Provision of a gelatin-free treatment option is important to ensure access for all patients regardless of religious or cultural beliefs.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The excipients in avapritinib is not an equality issue that NICE can address in a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope have been made to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues have been identified during the scoping process.

**Approved by Associate Director (name):** ...Linda Landells.....

**Date:** ...15 November 2023.....